Monitoring the frequency of side effects of drugs

BMJ

Volumn 312, Issue 7043, 1996, Pages 1418-1419

  Martin, Richard ^a   Hilton, Sean ^a   Richards, Nicky ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Research scientist Doctors Independent Network   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVERSE DRUG REACTION; ANEMIA; ANXIETY; CARDIOTOXICITY; CONSTIPATION; DATA BASE; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSURIA; GENERAL PRACTICE; HEADACHE; HUMAN; LETTER; MEDICAL RECORD; MONITORING; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; VERTIGO;

ADVERSE DRUG REACTION REPORTING SYSTEMS; FAMILY PRACTICE; GREAT BRITAIN; HUMANS;

EID: 0029943848     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.312.7043.1418d     Document Type: Letter

References (5)

1. Bracchi R. Drug companies should report side effects in terms of frequency. BMJ 1996; 312: 442. (17 February.)
2. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125–31.
3. Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 39: 223–226.
4. Martin RM. The Doctors Independent Network database: background and methodology. Pharmaceutical Medicine 1995; 9: 165–176.
5. Asscher AW, Parr GD, Whitmarsh VB. Towards the safer use of medicines. BMJ 1995; 311: 1003–5.